Tadalafil 20 mg/ml, 30 ml

$39.99

Tadalafil is a phosphodiesterase type 5, or PDE5, inhibitor supplied as a 20 mg/ml liquid research compound in a 30 ml bottle. It is intended for controlled laboratory investigation of PDE5 activity, vascular pathways, smooth muscle function and related biological mechanisms.

The solution is formulated for use in professional research environments where a consistent concentration is required for established laboratory procedures.

Storage: Store at room temperature, protect from direct sunlight and keep the container tightly closed.
Classification: Laboratory research compound.
Important: For laboratory research only. Not intended for human or veterinary use.

Product Description

Tadalafil is a phosphodiesterase type 5, or PDE5, inhibitor supplied as a 20 mg/ml liquid research compound in a 30 ml bottle. It is intended for controlled laboratory investigation of PDE5 activity, vascular pathways, smooth muscle function and related biological mechanisms.

The solution is formulated for use in professional research environments where a consistent concentration is required for established laboratory procedures.

Storage: Store at room temperature, protect from direct sunlight and keep the container tightly closed.
Classification: Laboratory research compound.
Important: For laboratory research only. Not intended for human or veterinary use.

Compound Information
MOLECULAR PROFILE
TypeSynthetic compound
CategoryResearch Compound
Purity≥99%
FormLyophilized powder
STORAGE REQUIREMENTS
Lyophilized (powder)

-20°C · 24+ months

Reconstituted

2–8°C · ~30 days

Certificate of Analysis

Third-party tested for purity and quality.

PURITY
0 %
Variant GLP3-RT 10mg
Lot # REF0001
Labeled 20mg
Actual 22.61mg
Tested APR 15, 2026

Coming soon

Research
New England Journal of Medicine

Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial

2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.

New England Journal of Medicine

Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial

2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.

New England Journal of Medicine

Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial

2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.

Related Research

COA Request

Researcher verification.
kelvian Labs sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.
By proceeding you affirm the statements above are true. Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration.

Not a researcher? Exit